Posted by Michael Wonder on 23 Nov 2016
NICE reviews multiple myeloma drug and approves for routine use
23 November 2016 - Hundreds of patients set to benefit after NICE draft guidance recommends pomalidomide, a drug that treats some people with bone marrow cancer, for routine use on the NHS.
Pomalidomide – a type of biological therapy – is used to treat patients whose cancer has come back after 3 previous treatments, including both lenalidomide and bortezomib. Around 620 patients would be eligible for treatment with this drug a year.
